www.medical-devices.tech
22
'26
Written on Modified on
Cathpax Clinical Study Confirms Nova-X Sets New Benchmark in Radiation Protection for Interventional Medicine
Cathpax announces final NOVARAD clinical study results, showcasing Nova-X system's superior radiation protection for interventional teams.
cathpax.com
Cathpax has announced the final results of the NOVARAD clinical study, demonstrating that its Nova-X® full-body, team-wide radiation protection system delivers an unprecedented level of protection for interventional physicians and staff. The study shows that Nova-X reduces radiation exposure to the main operator in interventional neuroradiology by a factor of eleven, addressing both radiation-induced diseases and the widespread musculoskeletal disorders associated with conventional lead aprons.
First global study of its kind
NOVARAD is the world’s first clinical study to comprehensively assess X-ray exposure across multiple anatomical areas in interventional neuroradiology. Conducted as a multicentric, two-arm prospective trial, it analyzed 178 procedures across four leading French hospitals, comparing standard protection methods with the Nova-X system.
Using high-precision dosimeters, the study measured exposure in seven anatomical regions. Results showed:
- 11× lower dose to the head and arms
- 38× lower dose to the feet
- >90% overall dose reduction for operators when using Nova-X
Average whole-body exposure for the primary operator dropped from 11.1 µSv per procedure to 1.0 µSv, confirming a step-change in occupational radiation safety.
Beyond radiation: tackling musculoskeletal disorders
Traditional lead personal protective equipment offers only partial shielding and contributes significantly to chronic musculoskeletal injuries—affecting around 66% of interventional physicians. NOVARAD results indicate that Nova-X enables safe operation without a lead apron, opening the door to improved ergonomics, longer careers, and broader workforce participation, including for younger physicians and women during pregnancy.
Clinical and professional impact
Clinical leaders involved in the study highlighted the system’s ability to protect staff without disrupting established workflows, while enabling operators to focus fully on patient care. The findings support Nova-X as a viable replacement for conventional personal protection equipment, with the potential to redefine safety standards in catheterization laboratories.
A new era for interventional safety
According to Cathpax, the study also challenges long-standing assumptions about radiation monitoring, revealing that exposure is highly non-uniform across the body—calling for more comprehensive protection and measurement approaches.
With NOVARAD validating Nova-X’s unmatched radioprotective performance, Cathpax is preparing for commercial rollout, initially focusing on the European market. The results mark a significant milestone in interventional medicine, setting a new reference for radiation protection, operator safety, and long-term workforce sustainability.
www.cathpax.com
Beyond radiation: tackling musculoskeletal disorders
Traditional lead personal protective equipment offers only partial shielding and contributes significantly to chronic musculoskeletal injuries—affecting around 66% of interventional physicians. NOVARAD results indicate that Nova-X enables safe operation without a lead apron, opening the door to improved ergonomics, longer careers, and broader workforce participation, including for younger physicians and women during pregnancy.
Clinical and professional impact
Clinical leaders involved in the study highlighted the system’s ability to protect staff without disrupting established workflows, while enabling operators to focus fully on patient care. The findings support Nova-X as a viable replacement for conventional personal protection equipment, with the potential to redefine safety standards in catheterization laboratories.
A new era for interventional safety
According to Cathpax, the study also challenges long-standing assumptions about radiation monitoring, revealing that exposure is highly non-uniform across the body—calling for more comprehensive protection and measurement approaches.
With NOVARAD validating Nova-X’s unmatched radioprotective performance, Cathpax is preparing for commercial rollout, initially focusing on the European market. The results mark a significant milestone in interventional medicine, setting a new reference for radiation protection, operator safety, and long-term workforce sustainability.
www.cathpax.com
